Presence of a survival benefit of HLA-incompatible living donor kidney transplantation compared to waiting or HLA-compatible deceased donor kidney transplantation with a long waiting time

  • Koo, Tai Yeon
  • Lee, Ju Han
  • Min, Sang-Il
  • Lee, Yonggu
  • Kim, Myung Soo
  • 외 7명
Citations

WEB OF SCIENCE

15
Citations

SCOPUS

18

초록

HLA-incompatible living donor kidney transplantation (LDKT) is one of efforts to increase kidney transplantation opportunity for sensitized patients with kidney failure. However, there are conflicting reports for outcomes of HLA-incompatible kidney transplantation compared to patients who wait for HLA-compatible deceased donor kidney transplantation (DDKT) in the United States and United Kingdom. Waiting for an HLA-compatible DDKT is relatively disadvantageous in Korea, because the average waiting time is more than five years. To study this further, we compared outcomes of HLA-incompatible LDKT with those who wait for HLA-compatible DDKT in Korea. One hundred eighty nine patients underwent HLA-incompatible LDKT after desensitization between 2006 and 2018 in two Korean hospitals (42 with a positive complement-dependent cytotoxicity cross-match, 89 with a positive flow cytometric cross-match, and 58 with a positive donor-specific antibody with negative cross-match). The distribution of matched variables was comparable between the HLA-incompatible LDKT group and the matched control groups (waiting-list-only group; and the waiting-list-or-HLA-compatible-DDKT groups; 930 patients each). The HLA-incompatible LDKT group showed a significantly better patient survival rate compared to the waiting-list-only group and the waiting-list-or-HLA-compatible-DDKT groups. Furthermore, the HLA-incompatible LDKT group showed a significant survival benefit as compared with the matched groups at all strength of donor-specific antibodies. Thus, HLA-incompatible LDKT could have a survival benefit as compared with patients who were waitlisted for HLA-compatible DDKT or received HLA-compatible DDKT in Korea. This suggests that HLA-incompatible LDKT as a good option for sensitized patients with kidney failure in countries with prolonged waiting times for DDKT.

키워드

desensitizationdonor-specific antibodyHLA incompatiblekidney transplantationwaiting timeANTIBODY-MEDIATED REJECTIONCROSS-MATCHRENAL-TRANSPLANTATIONRECIPIENTSRITUXIMABDESENSITIZATIONPREDICTIONMANAGEMENTOUTCOMESTHERAPY
제목
Presence of a survival benefit of HLA-incompatible living donor kidney transplantation compared to waiting or HLA-compatible deceased donor kidney transplantation with a long waiting time
저자
Koo, Tai YeonLee, Ju HanMin, Sang-IlLee, YongguKim, Myung SooHa, JongwonKim, Soon IlAhn, CurieKim, Yu SeunKim, JayounHuh, Kyu HaYang, Jaeseok
DOI
10.1016/j.kint.2021.01.027
발행일
2021-07
유형
Article in Press
저널명
Kidney International
100
1
페이지
206 ~ 214